None of the AIDS vaccine candidates being evaluated in clinical trials can cause HIV infection, yet some volunteers may still become HIV infected during the course of a trial through risk behaviors such as sexual activity or injection drug use. These volunteers may therefore need antiretrovirals (ARVs) to treat their HIV infection. The provision of this treatment to trial volunteers has been an important subject for organizations that conduct AIDS vaccine research and the communities where this work occurs. The ethical guidance for managing these patients is described and current practices of referral to treatment programmes outlined.
Vax Online Primer